Atlas
Back to Pharma Services
Founder / Operator·Pharma Services

Bruce Vielle

Chief Executive Officer at Meribel Pharma Solutions

Paris, France

BV
LinkedIn
Why they matter

Just took the CEO seat at FAMAR days after building and exiting Meribel Pharma Solutions — a rare operator with fresh, live scars on two European CDMO platforms.

Background

Bruce Vielle is a French industrial operator with an engineering background and an Executive MBA from HEC Paris, who built his career running multi-site pharma and animal-health manufacturing operations (Unither, Vétoquinol). He was CEO of Synerlab from 2019, then became founding CEO of Meribel Pharma Solutions in 2024-2025 when Blue Wolf Capital Partners merged Synerlab with seven carved-out Recipharm sites into a 13-site European CDMO platform. On August 3, 2026 — days before this record was compiled — he was named CEO of FAMAR, a separate Greece-headquartered European CDMO, succeeding interim CEO Dr. Riku Rautsola.

Notable deals

  • 2019
    Named President/CEO of Synerlab Group, a French pharma CDMO, succeeding Pierre Banzet
  • 2024
    Tapped by Blue Wolf Capital to lead new CDMO platform combining Synerlab with 7 carved-out Recipharm sites
  • 2025
    Launched Meribel Pharma Solutions as founding CEO, a 13-site, 3-country CDMO platform
  • 2026
    Appointed Chief Executive Officer of FAMAR, a Greece-headquartered European CDMO

Call-prep brief

Bruce Vielle — Background

  • Engineer by training, Executive MBA (HEC Paris); Lean/Six Sigma specialist.
  • Career path: site director at Unither (2008-2013) → industrial director/COO at Vétoquinol (2013-2018) → President/CEO of Synerlab (2019-2024) → founding CEO of Meribel Pharma Solutions (2024-2026) → CEO of FAMAR (since Aug 3, 2026).

Current focus

  • Days into the FAMAR mandate, taking over from interim CEO Dr. Riku Rautsola; likely still in listen-and-diagnose mode on FAMAR's 6 production sites across Greece, Italy and Spain.

What he cares about

  • Building "niche, agile, mid-sized" CDMO platforms rather than chasing scale for its own sake (his own framing at the Meribel launch).
  • Operational execution: multi-site lean manufacturing, integration of carved-out/acquired sites, culture-blending after M&A.

Recent moves / sensitivities

  • He left Meribel Pharma Solutions only ~16 months after its April 2025 launch — worth probing tactfully whether this reflects a better opportunity at FAMAR or friction with Blue Wolf Capital's ownership/strategy at Meribel. Handle with care; he is brand-new in the FAMAR seat and may not want to discuss the Meribel exit on the record yet.

Questions for the call

  1. What drove the timing of the move to FAMAR so soon after standing up Meribel — opportunity, or a strategic disagreement at the platform he built?
  2. Which parts of the Synerlab/Recipharm integration playbook are transferable to FAMAR's site network, and which aren't?
  3. Independent of his own move, how does he see Blue Wolf Capital's appetite for further European CDMO consolidation now that he's no longer running Meribel?

Outreach draft

Subject
Congratulations on your new role at FAMAR
Hi Bruce, Congratulations on stepping into the CEO role at FAMAR — quite a fast follow after standing up Meribel Pharma Solutions from the Synerlab and Recipharm sites. We work with a private equity deal team focused on the pharma services and CDMO landscape in Europe, and your operating view across two very different platform integrations in the same 18 months would be genuinely valuable to us. We're not looking for anything confidential — just your perspective on where mid-sized CDMOs are headed and what separates a platform that scales well from one that doesn't. Would you have 20-30 minutes for a call in the coming weeks? Best, [Placeholder Name]

Linked companies

Sources